Latest Video Updates

Upcoming Oncology Education Events

OncologyEducation Events Video Archives

Oncology Clinical News

Novartis to Buy Cancer-Drug Maker Endocyte for $2.1 Billion


Read full article.

A Year Early, Merck Touts Good Kidney Cancer News to Push Rival BMS

(Xconomy New York) Oct 18, 2018 - Merck could soon join rival Bristol-Myers Squibb in making immunotherapy an option for kidney cancer patients who have never had treatment before. Merck reported today that its blockbuster pembrolizumab (Keytruda) has hit its marks much earlier than expected in an 861-person Phase 3 study called Keynote-426. Merck tested a combination of pembrolizumab and axitinib (Inlyta), an approved kidney cancer drug from Pfizer, comparing it with sunitinib (Sutent), another approved drug that works in similar fashion to axitinib.
Read full article.

Powered by OBR Oncology